AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06271239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group (ViviFrail)
Description: The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
Study NCT06271239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Suggestions for a Healthy Life (CG)
Description: The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
Study NCT04868942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisting to the event
Description: Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management
Study NCT06448975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep cervical Lymphovenous Bypass
Description: Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
Study NCT04719520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wireless vibrating caller
Description: using the wireless vibrating caller to notify the patient's family to the operating room
Study NCT06391658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: Functional training was performed for eigth weeks. The group participated on the supervised training once a week and twice a week at home. The training was arranged in a circuit method, consisting of three to four blocks with two to three exercises each, with an execution time of two minutes and recovery of thirty seconds between exercises and one minute between each block. The exercises emphasized integrated, functional and multi-joint movements for mobility, flexibility, strength, power and muscular endurance with overload, as well as agility, speed and balance exercises.
Study NCT05933213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mescaline sodium enteric-coated tablets
Description: Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 432 Hertz frequency music
Description: 432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
Study NCT05933213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morte-mescaline
Description: Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
Study NCT05933213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: glucocorticoids
Study NCT05933213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: glucocorticoids
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
Study NCT05447000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfullness Based Stress Reduction (MBSR) intervention
Description: Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
Study NCT05447000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Relaxation Exercises intervention
Description: Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
Study NCT05447000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT04848311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph nodes dissection at 253 station assisted by ICG
Description: In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
Study NCT06117345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PICU Journal
Description: A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotpack
Description: Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
Study NCT05993000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack
Description: Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
Study NCT05483725 — intervention group
Intervention type: BIOLOGICAL
Intervention: Booster dose of mRNA vaccine
Description: Administration of SARS-CoV-2 mRNA vaccine.
Study NCT05301153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: real time PCR , ELISA
Description: Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
Study NCT05998941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2868 injection
Description: TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
Study NCT05998941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
Study NCT05998941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Cisplatin injection can inhibit the DNA replication process of cancer cells
Study NCT05998941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin injection
Description: Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
Study NCT05998941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab injection
Description: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
Study NCT05420974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG
Description: NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
Study NCT05838547 — intervention group
Intervention type: DRUG
Intervention: 64Cu-25%-CANF-Comb
Description: Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 18 months.
Study NCT06410170 — intervention group
Intervention type: DEVICE
Intervention: MIRA Device
Description: At home diagnostic testing
Study NCT05838547 — intervention group
Intervention type: DRUG
Intervention: 64Cu-25%-CANF-Comb
Description: Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
Study NCT05360901 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IntelliCare with automated motivational messaging
Description: Digital mental health intervention with automated motivational messaging
Study NCT05285670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital counseling plus interactive two-way SMS dialogue
Description: We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
Study NCT06002737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel
Description: Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
Study NCT06002737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel
Description: Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
Study NCT05711836 — intervention group
Intervention type: GENETIC
Intervention: HLA-genotyping
Description: HLA genotyping in DNA samples from peripheral blood of patients and controls
Study NCT05739214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before
Study NCT05739214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before
Study NCT04617054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106
Description: 600mg QD for each subjects.
Study NCT04432389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLOB
Description: After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
Study NCT04432389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
Study NCT05814146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate bicarbonate concentration
Description: Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions
Study NCT05814146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate concentration
Description: Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions
Study NCT05814146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate bicarbonate concentration - telemetry monitoring
Description: Patients will be monitored with telemetry on both arms of the trial.
Study NCT05814146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate concentration - telemetry monitoring
Description: Patients will be monitored with telemetry on both arms of the trial.
Study NCT06202339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaRT seeds
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study NCT05106218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurroundScope
Description: The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
Study NCT05106218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscope
Description: The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
Study NCT04697602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stepwise dose titration of febuxostat and low-dose colchicine
Description: Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
Study NCT04697602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dose febuxostat and low-dose colchicine
Description: Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
Study NCT05745610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shen Hai Long Capsule
Description: 3 times/day (9 capsules/day) for 12 weeks
Study NCT05745610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sheng Jing Capsule
Description: 3 times/day (12 capsules/day) for 12 weeks
Study NCT05359809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graspin Palmar Reflex Stimulation
Description: The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
Study NCT05605548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
Study NCT05623072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: 20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
Study NCT05623072 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 20 min, vmPFC Sham tDCS
Study NCT04270136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mastectomy
Description: breast cancer non conserving surgery
Study NCT04402346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted pancreas transection
Description: Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
Study NCT04402346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapler assisted pancreas transection
Description: Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
Study NCT05974007 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant immunochemotherapy
Description: Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
Study NCT05974007 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate